

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



March 16, 2026

Company name: PeptiDream Inc.
Representative: Patrick C. Reid, President and CEO
(Securities code: 4587; TSE Prime Market)
Inquiries: Yuko Okimoto, Head of Investor Relations
(Tel: +81-44-223-6612)

Notice Concerning Borrowing of Funds (Refinancing)

KANAGAWA, JAPAN – March 16, 2026 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced that it entered into a syndicated loan agreement under the "Mizuho Eco Finance*1" program, arranged by Mizuho Bank, Ltd., for the purpose of refinancing existing borrowings (the "Existing Borrowings") (the "Refinancing"), as described below.

1. Purpose of the Refinancing

On March 28, 2022, PeptiDream acquired the radiopharmaceutical business from FUJIFILM Toyama Chemical Co., Ltd., and in connection with the funding for the acquisition of the relevant business, entered into a syndicated loan agreement with Mizuho Bank, Ltd. acting as arranger and agent (please refer to the "Notice Concerning Borrowing of Funds" dated March 22, 2022 and the "Notice Concerning Borrowing of Funds" dated November 9, 2023). The Refinancing is being implemented prior to the maturity date of the Existing Borrowings, March 28, 2027, after taking into consideration the external business environment and other factors. Through the Refinancing, PeptiDream intends to apply the proceeds to the repayment of the Existing Borrowings and to further strengthen the stability of its financial base, including a reduction in interest expenses. *2

2. Outline of the Refinancing

| | | |
|-----|-------------------------|-------------------|
| (1) | Loan Amount | 16.44 billion yen |
| (2) | Contract Execution Date | March 16, 2026 |
| (3) | Drawdown Date | March 31, 2026 |

| | | |
|-----|----------|---------------------------------|
| (4) | Term | 7.5 years |
| (5) | Arranger | Mizuho Bank, Ltd. |
| (6) | Lenders | Domestic financial institutions |

3. Future Outlook

This refinancing has been factored in our consolidated financial forecasts for the fiscal year ending December 31, 2026, which was announced on February 16, 2026, and there are no changes to our forecast.

*1 Mizuho Eco Finance is an environmental evaluation-based financing product designed to promote initiatives toward the transition to a decarbonized society. Companies are assessed on their efforts to disclose information related to environmental considerations across five rating levels (AA, A, B, C, and D). This financing product is offered to companies that achieve a rating of A or higher. Preferential interest rates are applied based on the company's progress in reducing its environmental impact. PeptiDream has been highly evaluated for meeting the indicators used in the assessment model, including its targets related to greenhouse gas (GHG) emissions from business activities, such as aiming to achieve carbon neutrality by reducing Scope 1 and Scope 2 emissions by 100% by fiscal year 2030 compared to fiscal year 2023, and reducing Scope 3 emissions by 20% over the same period, as well as having certified by the Science Based Targets initiative ("SBTi").

*2 As stated in the consolidated financial results for the fiscal year ended December 31, 2025, as a result of having recorded an operating loss in that fiscal year, PeptiDream did not satisfy the financial covenants set forth in its syndicated loan agreements entered into with multiple financial institutions (with an outstanding balance of 17,100,000 thousand yen as of the end of the previous consolidated fiscal year). However, through the Refinancing, PeptiDream has determined that no material uncertainty exists regarding the going concern assumption.